Trending NewsTrending NewsNASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $522.38 +6.04 (+1.17%) Closing price 04:00 PM EasternExtended Trading$519.82 -2.56 (-0.49%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$515.30▼$528.9950-Day Range$470.72▼$557.9652-Week Range$377.02▼$560.25Volume936,619 shsAverage Volume976,911 shsMarket Capitalization$132.58 billionP/E Ratio30.41Dividend YieldN/APrice Target$573.83Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development. Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets. These medicines are designed to address the underlying cause of cystic fibrosis for eligible patients with specific genetic mutations. The company has expanded beyond cystic fibrosis through its collaboration with CRISPR Therapeutics on Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia. Vertex also markets Journavx, a non-opioid treatment for moderate to severe acute pain, and continues to develop potential therapies for conditions including type 1 diabetes and kidney disease. Vertex serves patients through commercial operations and partnerships across North America, Europe and other international markets. Reshma Kewalramani has served as the company’s president and chief executive officer since 2017.AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreVRTX MarketRank™: Vertex Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 138th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 20 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Vertex Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.53% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 9.53% in the coming year, from $16.69 to $18.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 30.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 30.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.98.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 7.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vertex Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.86% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 5.03.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently increased by 1.23%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.78 News SentimentVertex Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Vertex Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 36 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows30 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,874,834.00 in company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesVertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord GenuitySeptember 24 at 12:45 PM | theglobeandmail.comWill Vertex's Kidney Disease Pipeline Be a New Growth Engine?September 24 at 12:45 PM | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy RatingSeptember 24 at 7:44 AM | finance.yahoo.comVertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress ContinuesSeptember 24 at 1:17 AM | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Vertex Pharmaceuticals (VRTX)September 23 at 3:17 PM | theglobeandmail.comVertex Posts Positive Phase II Data on Kidney Disease DrugSeptember 23 at 3:17 PM | finance.yahoo.comLeerink Partners Begins Coverage on Vertex Pharmaceuticals (NASDAQ:VRTX)September 23 at 1:30 AM | americanbankingnews.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of 2026. Since then, VRTX shares have increased by 15.2% and is now trading at $522.38. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Monday, August, 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing the consensus estimate of $4.74 by $0.01. The business's quarterly revenue was up 12.5% on a year-over-year basis. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Vertex Pharmaceuticals: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others. Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' top institutional shareholders include BlackRock Inc. (9.50%), State Street Corp (4.68%), Wellington Management Group LLP (1.28%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.22%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include Salesforce (CRM), Chevron (CVX), Qualcomm (QCOM), AbbVie (ABBV), Home Depot (HD), CocaCola (KO) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/03/2026Today9/24/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 VRTX's financial health is in the Green zone, according to TradeSmith. VRTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$573.83 High Price Target$665.00 Low Price Target$442.00 Potential Upside/Downside+9.8%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$17.18 Trailing P/E Ratio30.41 Forward P/E Ratio31.30 P/E Growth2.26Net Income$3.95 billion Net Margins35.00% Pretax Margin41.90% Return on Equity23.09% Return on Assets16.72% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio2.74 Sales & Book Value Annual Sales$12.00 billion Price / Sales11.05 Cash Flow$17.83 per share Price / Cash Flow29.30 Book Value$73.57 per share Price / Book7.10Miscellaneous Outstanding Shares253,800,000Free Float253,297,000Market Cap$132.58 billion OptionableOptionable Beta0.32 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:VRTX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
